Author

Sa Deok Hong

Observed names: SA DEOK HONG, Sa deok Hong

Institution: CHA University

Observed institutions: CHA University Bundang Medical Center, CHA University

ORCID: 0000-0001-6165-6773

Observed ORCID: 0000-0001-6165-6773

OpenAlex ID: A5037095893

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer

2021 · Jin Hur, Mithun Ghosh, et al. · International Journal of Molecular Sciences · 36

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer

2023 · Yeong Gyu Jeong, Nar Bahadur Katuwal, et al. · Cancers · 23

Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer

2023 · Nar Bahadur Katuwal, Min Sil Kang, et al. · Journal of Experimental & Clinical Cancer Research · 17

Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer

2024 · Sa Deok Hong, Nar Bahadur Katuwal, et al. · International Journal of Molecular Sciences · 11

SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer

2025 · Mithun Ghosh, Min Sil Kang, et al. · Cell Death and Disease · 8

PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer

2023 · Mithun Ghosh, Min Sil Kang, et al. · International Journal of Molecular Sciences · 7

Intratumoral Injection of Allogeneic NK Cell With Chemotherapy in a Triple-negative Breast Cancer Preclinical Model

2025 · SA DEOK HONG, MIN SIL KANG, et al. · Anticancer Research · 2

Targeting oxidative phosphorylation with lixumistat overcomes PARP inhibitor resistance in ovarian cancer

2026 · Sa Deok Hong, Nar Bahadur Katuwal, et al. · Cell Death and Disease · 1

JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models

2026 · Min Sil Kang, Nar Bahadur Katuwal, et al. · British Journal of Cancer · 1

Abstract 4485: JPI-547, a novel dual inhibitor of PARP 1/2 and tankyrase 1/2 overcomes olaparib resistance in BRCA 1/2 mutant ovary and breast cancer preclinical model

2023 · Min Sil Kang, Nar Katuwal, et al. · Cancer Research · 1

Abstract P2-26-09: Synergistic activity of PI3K inhibitor in combination with AZD6738, ATR inhibitor in breast cancer preclinical model via DNA damage response pathway

2023 · Yong Wha Moon, Mithun Gosh, et al. · Cancer Research · 1

Abstract 7131: Targeting oxidative phosphorylation with lixumistat overcomes PARP inhibitor resistance in ovarian cancer

2026 · Sa deok Hong, Min Sil Kang, et al. · Cancer Research

886 Combined allogeneic NK cell and Herzuma® is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity

2022 · Yong Moon, Mithun Gosh, et al. · Journal for ImmunoTherapy of Cancer

Works count: 13

Citation count: 108

H-index: 6

I10-index: 4